Ovid Therapeutics
OVID
48 hedge funds and large institutions have $54.5M invested in Ovid Therapeutics in 2018 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 20 increasing their positions, 11 reducing their positions, and 9 closing their positions.
82% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 11
9% more capital invested
Capital invested by funds: $49.8M → $54.5M (+$4.7M)
2.43% more ownership
Funds ownership: 28.65% → 31.09% (+2.4%)
0% more funds holding
Funds holding: 48 → 48 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Cowen Inc
New York
|
+$5.69M |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$2.29M |
| 3 |
BlackRock
New York
|
+$1.03M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$380K |
| 5 |
State Street
Boston,
Massachusetts
|
+$301K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$2.2M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$993K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$612K |
| 4 |
Millennium Management
New York
|
-$380K |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$333K |
OVID Hedge Fund Activity: Q2 2018 in Review
48 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q2 2018, worth a combined $54.5M — up 9.4% from $49.8M a quarter earlier.
Fund positioning in OVID was balanced in Q2 2018: 9 funds opened new positions, 9 closed out, 20 added to existing stakes and 11 trimmed.
The largest buyer was Cowen Inc, opening a new position worth an estimated $5.69M. The largest seller was Jennison Associates, cutting an estimated $2.2M.
- 48 institutional investors held Ovid Therapeutics (OVID) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $54.5M of Ovid Therapeutics stock for Q2 2018, up 9.4% quarter-over-quarter.
- 9 funds opened new Ovid Therapeutics positions in Q2 2018 and 9 closed out, a net change of 0 holders.
- The largest Ovid Therapeutics buyer in Q2 2018 was Cowen Inc, an estimated $5.69M added.
- The largest Ovid Therapeutics seller in Q2 2018 was Jennison Associates, an estimated $2.2M sold.
Based on aggregated 13F filings for Q2 2018.